Exelixis Trading Volume Surges 388% to $568 Million Ranking 178th in Daily Volume

On May 14, 2025, Exelixis saw a significant surge in trading volume, reaching $568 million, marking a 388.01% increase from the previous day. This substantial rise placed Exelixis at the 178th position in the day's trading volume rankings. The company's stock price also experienced a notable increase, rising by 20.84%.

Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for Cabozantinib, a drug used to treat advanced renal cell carcinoma. This approval expands the indications for Cabozantinib, allowing it to be used in combination with nivolumab and ipilimumab for the treatment of intermediate- and poor-risk advanced renal cell carcinoma. The approval is based on the results of the CheckMate-9ER trial, which demonstrated a significant improvement in progression-free survival and overall survival for patients treated with the combination therapy compared to sunitinib.

Exelixis also reported positive results from its Phase 3 trial of Cabozantinib in combination with atezolizumab for the treatment of hepatocellular carcinoma. The trial met its primary endpoint of overall survival, showing a statistically significant improvement compared to sorafenib. This result supports the potential use of Cabozantinib in combination with atezolizumab as a new treatment option for patients with advanced hepatocellular carcinoma.

In addition to these clinical developments, Exelixis has been actively expanding its pipeline through strategic partnerships and collaborations. The company recently entered into a collaboration agreement with a leading biotechnology firm to develop novel therapies for cancer. This partnership aims to leverage the strengths of both companies to accelerate the development of innovative treatments for patients with unmet medical needs.